vinblastine sulfate 1 mg/ml solution for inj/inf
hospira uk limited - vinblastine sulfate - solution for inj/inf - 1 mg/ml - vinca alkaloids and analogues
vinblastine sulfate 1mg/ml solution for injection or infusion
pfizer healthcare ireland - vinblastine sulfate - solution for injection/infusion - 1 milligram(s)/millilitre - vinca alkaloids and analogues; vinblastine
bixel (bleomycin sulphate for injection 15 units)
cipla malaysia sdn bhd - bleomycin sulphate -
bleo-kyowa 15,000unit powder for solution for injection vials
kyowa kirin ltd - bleomycin sulfate - powder for solution for injection - 15000unit
blenoxane
bristol-myers squibb (nz) limited - bleomycin sulfate 15000 [iu] equivalent to to 10 mg. - powder for injection - 15000 iu - active: bleomycin sulfate 15000 [iu] equivalent to to 10 mg.
bleomycin mylan 15,000 iu (ph. eur.) = 15 u (usp) powder and solvent for solution for injection
central procurement & supplies unit ub002 industrial estate, san gwann sgn 3000, malta - powder and solvent for solution for injection - bleomycin sulfate 15000 i.u. - antineoplastic agents
bleomycin 15 milligram
lundbeck limited - bleomycin sulfate - 15 milligram
bleomycin lundbeck injection
lundbeck limited - bleomycin sulfate - pdr for soln inj/inf - 15 milligram
hospira bleomycin for injection, usp 15 units vial
hospira australia pty ltd - bleomycin sulfate, quantity: 15 iu - injection, powder for - excipient ingredients: sodium hydroxide; sulfuric acid - managment of the following neoplasms either as a single agent or in combination with other chemotherapeutic agents: squamous cell carcinoma, lymphomas, testicular carcinoma.
dbl vincristine sulfate 2mg/2ml injection vial
pfizer australia pty ltd - vincristine sulfate, quantity: 1 mg/ml - injection, solution - excipient ingredients: sulfuric acid; mannitol; water for injections; sodium hydroxide - vincristine sulfate is indicated in acute leukaemia - current practices of cancer chemotherapy involve the simultaneous use of several agents. for enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. it is rarely possible to achieve equally good results with single agent treatment. thus vincristine sulfate is often chosen as part of polychemotherapy because of its unique clinical toxicity (neuropathy). see dosage and administration for possible increased toxicity when used in combination therapy. it has been shown to be useful in combination with other oncolytic agents in hodgkin's disease, non-hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular and diffuse types), rhabdomyosarcoma, neuroblastoma, wilm's tumour, osteogenic sarcoma, mycosis fungoides, ewing's sarcoma, carcinoma of the uterine cervix, breast cancer, malignant melanoma, oat-cell carcinoma